Chizhou Dongsheng Pharmaceutical Co., Ltd signed the investment framework to receive CNY 45,000,000 in an equity round of funding on December 3, 2021. The transaction will include participation from new investors Jinling Pharmaceutical Company Limited for CNY 36,000,000 out of which CNY 28,000,000 will be added as registered capital and Nanjing Core Tech Co., Ltd. for CNY 9,000,000 out of which CNY 7,000,000 will be added as registered capital. Post the closing, the investors will hold 65% and 10% respectively through capital increase and acquisition transactions. The transaction has been approved at the 15th Meeting of the Jinling Pharmaceutical Company Limited 8th Directorate and is not subject to its shareholder's approval.

On December 29, 2021, the 15th session of the Jinling Pharmaceutical Company Limited's 8th directorate approved the transaction.